LONG-TERM EFFECT OF ANTIANGIOGENIC THERAPY FOR RETINOPATHY OF PREMATURITY Up to 5 Years of Follow-up

• DOI: 10.1097/iae.0b013e318275394a
• Publication Date: 2012-10-25T06:38:07Z
• Authors: María A. Martínez...; Shulamit Schwartz; Myriam L. Hernánd...; Veronica A. Kon-Jara; Gerardo García-Ag...; José L. Guerrero-...; R. V. Paul Chan; Hugo Quiroz–Mercado
• Keywords: Male; Biometry; Infant, Newborn; Infant; Angiogenesis Inhibitors; Gestational Age; Retinal Neovascularization; Antibodies, Monoclonal, Humanized; Refraction, Ocular; 3. Good health; Bevacizumab; 03 medical and health sciences; 0302 clinical medicine; Recurrence; Child, Preschool; Intravitreal Injections; Electroretinography; Birth Weight; Humans; Female; Prospective Studies; Infant, Premature; Follow-Up Studies

In Brief Purpose: To evaluate ocular function and systemic development in premature infants treated with intravitreal bevacizumab injections for retinopathy of prematurity over a period 5 years. Methods: A prospective, interventional, noncomparative case study. The primary outcome measure was visual acuity. secondary outcomes were structural assessment, other functional measurements, developmental state. Results: Eighteen eyes 13 consecutive patients divided into 3 groups: Group 1, Stage 4 unresponsive to previous conventional treatment (n = 4); 2, which difficult or impossible because inadequate visualization the retina 5); 3, newly diagnosed high-risk prethreshold threshold 9). All showed initial regression neovascularization. One patient recurrence neovascularization bevacizumab. Visual acuity preserved, median vision 20/25 (excluding 2 operated eyes). Twelve developed mainly low myopia years, an overall mean value 3.2 diopters. Electroretinograph normal that had no detachment. delay growth neurodevelopment, whereas all others within range. Conclusion: Five years follow-up small series suggest results apparently preserved development. Intravitreal blindness prevention without apparent effects.